Diagnostic Doubt.


FDA-cleared with an exclusive indication for reducing blood culture contamination¹

Clinical & cost effectiveness studies published in CID, JEN, AJIC, JCM and JHI*

Backed by a money-back, Clinical Performance Guarantee²

Confidence comes with blood culture results you can trust.

With one squeeze, the Steripath® Gen2 Initial Specimen Diversion Device® diverts and sequesters the most commonly contaminated portion of the blood prior to collection – ensuring specimen integrity —giving nurses, CNOs, and laboratorians the confidence that they are providing the very best patient care possible.

Get Started Today

Speak with a Clinical Specialist to get started down your path to Culture Confidence.

The Benefits

of significantly reducing blood culture contamination can make a huge impact at your hospital
Improve Patient Safety & Outcomes

Protect your patients from the harmful, unnecessary impacts of a sepsis misdiagnosis such as C. difficile and other antibiotic-resistant infections, acute kidney injury, extended hospital stay and HACs due to unnecessary and prolonged antibiotic treatment.3

Drive Antibiotic Stewardship

Reducing false-positive blood culture results with Steripath can reduce unnecessary broad-spectrum antibiotic days of therapy by as much as 37%.4


Reduce Unnecessary Costs

The use of Steripath is the single most effective intervention so far explored for reducing costs related to false-positive blood cultures and would save the typical 250-400-bed hospital $1.9 million or $186 per blood culture and prevent 34 HACs (including three C. difficile cases).

Impact CMS Quality Outcomes & Revenues

Significantly improving blood culture testing accuracy can help prevent up to 7% CMS revenue loss plus cost of initial care due to HAIs such as C. difficile infections, false-positive CLABSIs and MRSA, and increased length of stay and readmissions.5,6,7

What makes Steripath so effective?

Steripath's proprietary technology and easy-to-use design enable you to deliver the definitive diagnostic results your patients deserve

Steripath Gen2 Diversion Volume
Evidence-Based Diversion Volume

1.5-2.0mL is the diversion volume clinically proven effective in peer-reviewed, published, controlled studies.8

User-Controlled Active Diversion

Gentle negative pressure assists in drawing the diverted blood, critical for hard stick patients.

Designed to prevent bypassing diversion
Engineered Compliance

Uniquely designed to prevent the end-user from collecting the specimen until diversion is complete.

Luer Extension
Clinically Proven for IV Starts

Steripath has been clinically proven effective with peripheral IV starts and venipuncture.*

Steripath secondary blood collection pathway
Secondary Collection Pathway

A secondary blood collection pathway automatically opens for specimen collection once diversion is complete.

Best Practice Kit (BD)
Available in a Customizable Kit

Everything you need to standardize blood culture collection best practices.


"Steripath may be the easiest and fastest route to significantly impact antibiotic stewardship within the hospital."

Lindsey Nielsen, PhD, CPEP Fellow, University of Nebraska Medical Center

Thank you! We will be in contact with you shortly. In the meantime, please visit to learn more about Steripath®.

All the best,
Magnolia Medical

We're sorry. An error occurred during the submission of this form. Please try submitting the form again.


  1. Indicated to reduce the frequency of blood culture contamination when contaminants are present, compared to standard method controls without diversion
  2. Additional terms and conditions may apply
  3. Robert Garcia, et al., "Multidisciplinary team review of best practices for collection and handling of blood cultures to determine effective interventions for increasing the yield of true-positive bacteremia, reducing contamination, and eliminating false-positive central line associated bloodstream infections." American Journal of Infection Control, 2017
  4. D. Chang, et al. “Impact of Blood Culture Diversion Device and Molecular Pathogen Identification on Vancomycin Use.” Society of Healthcare Epidemiology of America (SHEA) Conference (Spring 2017)
  5. Skoglund, E., et al (2019). “Estimated Clinical and Economic Impact Through Use of a Novel Blood Collection Device [Steripath] to Reduce Blood Culture Contamination in the Emergency Department: A Cost-Benefit Analysis.” J Clin Microbiol. 57: e01015-18
  6. Boyce et al., "Obtaining Blood Cultures by Venipuncture versus from Central Lines: Impact on Blood Culture Contamination Rates and Potential Effect on Central Line–Associated Bloodstream Infection Reporting." AJIC 2013
  7. Reveles, et al, "The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001-2010." AJIC 2014
  8. Richard G. Patton Blood Culture Contamination Definitions Can Obscure the Extent of Blood Culture Contamination: A New Standard for Satisfactory Institution Performance Is Needed. Infection Control & Hospital Epidemiology, Available on CJO 2016 doi:10.1017/ice.2016.30

* Multiple studies (Rupp M., et al; “Reduction in Blood Culture Contamination Through Use of Initial Specimen Diversion Device.” Clinical Infectious Diseases (Aug. 2017); Bell, M., et al. (2018). Effectiveness of a Novel Specimen Collection System in Reducing Blood Culture Contamination Rates. Journal of Emergency Nursing, 44(6): 570-5753; Zimmerman, F., et al.: “Reducing blood culture contamination using an initial specimen diversion device. American Journal of Infection Control (2018); Chang D., et al; Impact of Blood Culture Diversion Device and Molecular Pathogen Identification on Vancomycin Use. Society of Healthcare Epidemiology of America (SHEA) Conference (Spring 2017); Doern, G., et al. “A Comprehensive Update on the Problem of Blood Culture Contamination and a Discussion of Methods for Addressing the Problem.” Clinical Microbiology Reviews (2019); Skoglund, E., et al.: "Estimated Clinical and Economic Impact Through Use of a Novel Blood Collection Device (Steripath) to Reduce Blood Culture Contamination in the Emergency Department: A Cost-Benefit Analysis.” J Clin Microbiol. (2019); Geisler, B., et al.: “A Model to Evaluate the Impact of Hospital-Based Interventions Targeting False-Positive Blood Cultures on Economic and Clinical Outcomes.” Journal of Hospital Infection (2019))